Clinical Trial Update: A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4) [Phase 3]

View source ↗

Summary

Phase 3 study COMBINE 4 evaluated weekly IcoSema (insulin icodec + semaglutide) versus daily insulin glargine in Type 2 Diabetes; study completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Type 2 Diabetes Mellitus

Drugs mentioned

• IcoSema (insulin icodec and semaglutide)
• Insulin Glargine (insulin glargine)

Snippet

Sponsor: Novo Nordisk A/S | Conditions: Type 2 Diabetes | Phase 3 | Status: COMPLETED